CytomX Therapeutics
CTMX
142 hedge funds and large institutions have $739M invested in CytomX Therapeutics in 2018 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 62 increasing their positions, 44 reducing their positions, and 24 closing their positions.
128% more call options, than puts
Call options by funds: $2.74M | Put options by funds: $1.2M
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
41% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 44
6.11% more ownership
Funds ownership: 77.05% → 83.16% (+6.1%)
8% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 24
1% more funds holding
Funds holding: 141 → 142 (+1)
12% less capital invested
Capital invested by funds: $843M → $739M (-$104M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$18.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$14.3M |
| 4 |
Renaissance Technologies
New York
|
+$11.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TG
TRV GP
Boston,
Massachusetts
|
-$29M |
| 2 |
Millennium Management
New York
|
-$8.43M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$7.54M |
| 4 |
PA
Perceptive Advisors
New York
|
-$7.33M |
| 5 |
PC
PointState Capital
New York
|
-$4.38M |
CTMX Hedge Fund Activity: Q2 2018 in Review
142 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2018, worth a combined $739M — down 12% from $843M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new CTMX positions and 24 closed out — a net gain of 2 holders — while 62 added to existing stakes and 44 trimmed.
The largest buyer was BlackRock, adding an estimated $18.3M. The largest seller was TRV GP, exiting entirely with an estimated $29M sold.
- 142 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2018, up from 141 in Q1 2018.
- Funds reported $739M of CytomX Therapeutics stock for Q2 2018, down 12% quarter-over-quarter.
- 26 funds opened new CytomX Therapeutics positions in Q2 2018 and 24 closed out, a net change of +2 holders.
- The largest CytomX Therapeutics buyer in Q2 2018 was BlackRock, an estimated $18.3M added.
- The largest CytomX Therapeutics seller in Q2 2018 was TRV GP, an estimated $29M sold.
Based on aggregated 13F filings for Q2 2018.